Lonquex is a medicine that contains the active substance lipegfilgrastim. It is used to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients with cancer aged 2 years and older receiving cytotoxic chemotherapy. Cytotoxic chemotherapy (medicines that kill fast growing cells) commonly causes neutropenia because as well as killing cancer cells, it also kills other fast-growing cells such as neutrophils, leaving the patient at risk of infections. Lonquex is not used in patients receiving chemotherapy for chronic myeloid leukaemia (a cancer of the white blood cells) and myelodysplastic syndromes (a disease that can develop into a leukaemia).
Therapeutic Indication
### Therapeutic indication Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Therapeutic Area (MeSH)
N/AATC Code
L03AA14
ATC Item
lipegfilgrastim
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lipegfilgrastim | N/A | Lipegfilgrastim |
EMA Name
Lonquex
Medicine Name
Lonquex
Aliases
N/ANo risk management plan link.
